Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2023 First Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that thereare no false representations, misleading statements or material omissions contained inthis announcement and accept legal responsibility for the truthfulness, accuracy andcompleteness of the contents hereof.
IMPORTANT NOTICE:
? The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior managementof the Company hereby warrant the truthfulness, accuracy and completeness of the contents of thisquarterly report, and that there are no false representations, misleading statements or materialomissions contained herein, and severally and jointly accept legal responsibility.
? The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant thetruthfulness, accuracy and completeness of the financial information contained in this quarterly report.
? Whether the first quarterly financial statements have been audited.
□Yes √No
I. MAJOR FINANCIAL DATA(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
| Item | The Reporting Period (From January to March) | YoY change (%) |
| Revenues | 4,559,049,786.82 | -2.11 |
| Net profit attributable to shareholders of the listed company | 462,746,183.03 | 0.48 |
| Net profit attributable to shareholders of the listed company after deduction of extraordinary gains and losses | 446,772,473.94 | -2.28 |
| Net cash flow from operating activities | 248,084,750.71 | -71.55 |
| Basic earnings per share (RMB/share) | 0.2404 | -0.31 |
| Diluted earnings per share (RMB/share) | 0.2398 | -0.48 |
| Weighted average return on net assets (%) | 3.49 | Decreased by 0.35 percentage points |
| As at the end of the Reporting Period | As at the end of the previous year | Change as at the end of the Reporting Period as compared to the end of the previous year(%) | |
| Total assets | 36,193,051,015.06 | 35,729,253,651.41 | 1.30 |
| Owner's equity attributable to shareholders of the listed company | 13,365,070,332.08 | 13,121,820,410.55 | 1.85 |
Notes: From January to March 2023, the Company realized revenues of RMB4,559 million, representing a YoYdecrease of 2.11%. Chemical pharmaceuticals realized revenues of RMB2,250 million, representing a YoYdecrease of 16.09%, among which, RMB509 million were from respiratory formulation products, representinga YoY increase of 41.18%; RMB793 million were from gastroenterology products, representing a YoYdecrease of 25.23%; RMB577 million were from gonadotropic hormones, representing a YoY decrease of
21.60%; RMB199 million were from anti-infection products, representing a YoY decrease of 43.29%;andRMB122 million were from psychiatry products, representing a YoY decrease of 8.25%. APIs andintermediates products realized revenues of RMB1,454 million, representing a YoY increase of 3.44%.Traditional Chinese Medicine products realized revenues of RMB567 million, representing a YoY increase of
100.68%. Biological products realized revenues of RMB62 million, representing a YoY increase of 12.22%.Diagnostic reagents and equipment products realized revenues of RMB147 million from, representing a YoYdecrease of 9.54%. Health care products realized revenues of RMB40 million, representing a YoY increase of
46.99%.
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
| Item | For the Reporting Period | Explanation |
| Government grants recognized in profit or loss for the current period (excluding government grants closely related to the ordinary operating business of the Company and are entitled in fixed amount or quantity continuously according to the applicable national polices and standards) | 51,488,223.81 | Government grants through the profits and losses for the Period |
| Gains and losses on fair value changes incurred from financial assets held for trading, derivative financial assets, financial liabilities held for trading and derivative financial liabilities, and investment income on disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except for effective hedging activities related to the ordinary operating business of the Company | -18,242,051.06 | Gains or losses arising from changes in fair value of financial assets/liabilities held for trading, and investment gains from holding and disposal of financial assets/liabilities held for trading |
| Other non-operating income and expenses excluding the above items | -2,822,249.38 | Other non-operating income and expenses excluding the above items |
| Less: Effect of income tax | 7,100,276.22 | Effect of the above items on income tax |
| Effect of minority equity (after tax) | 7,349,938.06 | The portion of the above items to which minority shareholders are entitled |
| Total | 15,973,709.09 |
Explanations for classifying items of extraordinary gains and losses defined in the ExplanatoryAnnouncement No. 1 for Public Company Information Disclosures –Extraordinary Gains or Losses asitems of recurring gains or losses.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof
√Applicable □N/A
| Item | Change (%) | Explanation |
| Net cash flow from operating activities | -71.55 | Mainly due to the increase in procurement expenditure of raw materials and a decrease of cash collections of sales revenue during the Reporting Period. |
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and ReasonsThereof
Unit: Yuan Currency: RMB
| Balance Sheet | 31 March 2023 | 31 December 2022 | Change in proportion （%） | Main Reason |
| Financial liabilities held for trading | 4,759,250.98 | 755,634.43 | 529.84 | Mainly due to changes in exchange rates forward foreign exchange contracts. |
| Contract liabilities | 118,380,947.47 | 292,977,730.74 | -59.59 | Mainly because part of the contract payments received in advance in the Period which met the conditions for revenue recognition were recognized as revenues. |
| Employee benefits payable | 361,917,343.05 | 573,010,571.46 | -36.84 | Mainly due to the payment of the year end performance bonus for the previous year. |
| Treasury shares | 717,135,581.08 | 347,176,561.29 | 106.56 | Mainly due to increase of repurchase of shares during the Reporting Period. |
| Other comprehensive income | -42,580,905.41 | 4,704,473.53 | -1005.12 | Mainly due to changes in the fair value of other equity instrument investments. |
| Statement of Income | January to March 2023 | January to March 2022 | Change in proportion （%） | Main Reason |
| Financial expenses | -15,861,425.43 | -30,519,305.67 | N/A | Mainly due to an increase of financial expenses as a result of exchange losses. |
| Income from investments | 39,625,949.95 | 29,176,808.52 | 35.81 | Mainly due to the receipt of bonus payments during the Reporting Period. |
| Gains from changes in fair values | -27,478,190.74 | -54,151,999.18 | N/A | Mainly due to fluctuations in the market value of the securities investments held. |
| Losses of credit impairment | -15,459,174.59 | 217,773.10 | -7198.75 | Mainly due to the receivables and the increase in the expected credit loss for the Reporting Period as compared with the previous period. |
| Assets impairment loss | 1,837,691.27 | -5,309,013.21 | N/A | Mainly due to the provision for price decline of inventories for the Reporting Period decreased as compared with the previous period. |
| Non-operating income | 876,580.36 | 2,321,933.96 | -62.25 | Mainly due to the decrease in income from disposal of scrap items for the Reporting Period as compared to the previous period. |
| Non-operating expenses | 3,698,829.74 | 2,084,578.34 | 77.44 | Mainly due to the increase in expenditure of charitable donation for the Reporting Period as compared with the previous period. |
| Cash Flow Statement | January to March 2023 | January to March 2022 | Change in proportion （%） | Main Reason |
| Net cash flow from operating activities | 248,084,750.71 | 871,904,476.98 | -71.55 | Mainly due to the increase in procurement expenditure of raw materials and a decrease of cash collections of sales revenue during the Reporting Period. |
| Net cash flow from investing activities | -71,511,309.54 | -77,907,837.67 | N/A | Mainly due to the recovery of investment amount and the decreased investment of construction of new plants for the Reporting Period as compared with the previous period. |
| Net cash flow from financing activities | -118,644,351.81 | 62,714,553.34 | -289.18 | Mainly due to the decrease in repayment and borrowings received for the Reporting Period as compared with the previous period. |
| Effect of foreign exchange rate changes on cash | -47,773,910.21 | -12,259,201.98 | N/A | Mainly due to changes in foreign exchange rates resulting in an increase in exchange loss from foreign exchange funds held. |
| Net increase in cash and cash equivalents | 10,155,179.14 | 844,451,990.66 | -98.80 | Mainly due to the decrease in cash generated from ordinary operating activities and the increase in procurement expenditure of raw materials during the Reporting Period. |
II. SHAREHOLDERS(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with RestoredVoting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
| Total number of holders of ordinary shares as of the end of the Reporting Period | 87,173 | Total number of holders of preferred shares with restored voting rights as of the end of the Reporting Period (if any) | 0 | ||||
| Shareholdings of the top 10 shareholders | |||||||
| Name of shareholder | Nature of shareholder | Number of shares held | Percentage (%) | Number of shares held with selling restrictions | Pledge, mark or lock-up | ||
| Share status | Number | ||||||
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司) | Domestic non-state-owned legal person | 895,653,653 | 46.43 | 0 | Pledge | 95,679,725 | |
| Hong Kong Securities Clearing Company Limited | Unknown | 110,920,501 | 5.75 | 0 | Unknown | ||
| Might Seasons Limited | Foreign legal person | 51,931,021 | 2.69 | 0 | Unknown | ||
| Citibank, National Association | Unknown | 13,780,230 | 0.71 | 0 | Unknown | ||
| Huaxia Life Insurance Co., Ltd. - Own fund | Unknown | 11,854,118 | 0.61 | 0 | Unknown | ||
| He Zhong | Domestic natural person | 7,800,024 | 0.40 | 0 | Unknown | ||
| Agricultural Bank of China Limited - CSI 500 Exchange Traded Index Securities Investment Fund | Unknown | 7,010,694 | 0.36 | 0 | Unknown | ||
| Joincare Pharmaceutical Group Industry Co., Ltd. — the Second Phase Ownership Scheme under Medium to Long-term Business Partner Share Ownership Scheme (健康元药业集团股份有限公司－中长期事业合伙人持股计划之第二期持股计划) | Others | 6,275,372 | 0.33 | 0 | - | ||
| Industrial Bank Co., Ltd. - Caitong Asset Management Health Industry Hybrid Securities Investment Fund | Unknown | 6,000,000 | 0.31 | 0 | Unknown | ||
| 108 protfolio of national social security fund | Unknown | 5,857,721 | 0.30 | 0 | Unknown | ||
| Shareholdings of the top 10 shareholders without selling restrictions | |||||||
| Name of shareholder | Number of tradable shares held without selling restrictions | Class and number of shares | |||||
| Class of shares | Number | ||||||
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司) | 895,653,653 | Ordinary shares denominated in Renminbi | 895,653,653 | ||||
| Hong Kong Securities Clearing Company Limited | 110,920,501 | Ordinary shares denominated in Renminbi | 110,920,501 | ||||
| Might Seasons Limited | 51,931,021 | Ordinary shares denominated in Renminbi | 51,931,021 | ||||
| Citibank, National Association | 13,780,230 | Ordinary shares denominated in Renminbi | 13,780,230 | ||||
| Huaxia Life Insurance Co., Ltd. - Own fund | 11,854,118 | Ordinary shares denominated in Renminbi | 11,854,118 | ||||
| He Zhong | 7,800,024 | Ordinary shares denominated in Renminbi | 7,800,024 | ||||
| Agricultural Bank of China Limited - CSI 500 Exchange Traded Index Securities Investment Fund | 7,010,694 | Ordinary shares denominated in Renminbi | 7,010,694 | ||||
| Joincare Pharmaceutical Group Industry Co., Ltd. — the Second Phase Ownership Scheme under Medium to Long-term Business Partner Share Ownership Scheme (健康元药业集团股份有限公司－中长期事业合伙人持股计划之第二期持股计划) | 6,275,372 | Ordinary shares denominated in Renminbi | 6,275,372 | ||||
| Industrial Bank Co., Ltd. - Caitong Asset Management Health Industry Hybrid Securities Investment Fund | 6,000,000 | Ordinary shares denominated in Renminbi | 6,000,000 | ||||
| 108 protfolio of national social security fund | 5,857,721 | Ordinary shares denominated in Renminbi | 5,857,721 | ||||
| Description of connection or acting-in-concert relationship of the above shareholders | There was no connection or acting-in-concert relationship between Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company, and other shareholders; whether there is connection or acting-in-concert relationship among other shareholders is unknown. |
| Description of the participation of the top 10 shareholders and the top 10 shareholders without selling restrictions in margin financing and securities lending and refinancing business (if any) | As of the end of the Reporting Period, He Zhong, a shareholder, holds a total of 7,800,024shares of the Company, including 800,000 shares held through ordinary securities accounts and 7,000,024 shares held through credit securities accounts. |
| Description of the special repurchase account among the top 10 shareholders | As of the end of the Reporting Period, the special repurchase account of the Company (Special securities repurchase account of Joincare Pharmaceutical Group Industry Co., Ltd.) owned 58,122,392 shares in total, accounting for 3.01%. |
Note: Citibank, National Association is the depositary of the Company’s GDRs (Global Depository Receipts),the corresponding underlying domestic A Shares of GDRs shall be registered under its name according to thelaws; According to the depositary’s statistics, as of the end of the Reporting Period, the Company had a total of1,378,023 GDRs outstanding accounting for 21.59% of the total number of GDRs issued by the Company.
III. OTHER REMINDERSOther important information regarding the Company’s operations during the Reporting Period to whichinvestors should be reminded to pay attention.
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
Consolidated Balance Sheet
31 March 2023Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | 31 March 2023 | 31 December 2022 |
| Current assets: | ||
| Monetary funds | 14,458,474,995.37 | 14,808,488,110.96 |
| Financial assets held for trading | 85,646,883.17 | 109,015,664.98 |
| Notes receivable | 2,202,720,144.84 | 1,959,985,016.85 |
| Accounts receivable | 3,259,431,777.79 | 3,103,758,850.15 |
| Receivables financing | ||
| Prepayments | 457,539,057.82 | 364,265,142.57 |
| Other receivables | 56,254,117.17 | 52,535,740.14 |
| In which: Interests receivable | ||
| Dividends receivable | ||
| Inventories | 2,790,598,613.23 | 2,561,869,999.57 |
| Contract assets | ||
| Assets Held-for-sale | ||
| Non-current assets due within one year | 54,581,111.11 | 54,048,611.11 |
| Other current assets | 182,329,092.88 | 163,539,900.32 |
| Total current assets | 23,547,575,793.38 | 23,177,507,036.65 |
| Non-current assets: | ||
| Debt investment | ||
| Other debt investment | ||
| Long-term receivables | ||
| Long-term equity investment | 1,432,562,509.67 | 1,419,882,594.59 |
| Other equity instrument investments | 1,149,287,217.20 | 1,193,958,879.05 |
| Other non-current financial assets | ||
| Investment properties | 6,191,475.43 | 6,191,475.43 |
| Fixed assets | 5,230,295,232.48 | 5,265,200,110.91 |
| Construction in progress | 909,461,674.66 | 811,300,068.96 |
| Productive biological assets | ||
| Oil and gas assets | ||
| Right-of-use assets | 40,694,040.95 | 41,843,133.97 |
| Intangible assets | 832,112,818.49 | 802,115,125.75 |
| Development expenditures | 300,157,334.73 | 428,284,884.17 |
| Goodwill | 636,339,503.82 | 614,468,698.73 |
| Long-term deferred expenses | 290,036,796.09 | 277,867,716.95 |
| Deferred income tax assets | 506,141,586.79 | 533,861,743.26 |
| Other non-current assets | 1,312,195,031.38 | 1,156,772,182.99 |
| Total non-current assets | 12,645,475,221.68 | 12,551,746,614.76 |
| Total assets | 36,193,051,015.06 | 35,729,253,651.41 |
| Current liabilities: | ||
| Short-term loans | 2,099,069,713.00 | 2,126,050,615.06 |
| Financial liabilities held for trading | 4,759,250.98 | 755,634.43 |
| Notes payable | 1,659,215,210.65 | 1,635,906,989.22 |
| Accounts payable | 1,044,610,610.21 | 943,905,580.91 |
| Receipts in advance | ||
| Contract liabilities | 118,380,947.47 | 292,977,730.74 |
| Employee benefits payable | 361,917,343.05 | 573,010,571.46 |
| Taxes payable | 302,213,706.06 | 337,702,273.73 |
| Other payables | 3,650,990,302.39 | 3,680,334,360.88 |
| In which: Interests payable | ||
| Dividends payable | 11,892,804.66 | 12,252,074.84 |
| Liabilities held-for-sale | ||
| Non-current liabilities due within one year | 65,000,820.80 | 63,077,260.98 |
| Other current liabilities | 88,863,541.97 | 101,276,714.35 |
| Total current liabilities | 9,395,021,446.59 | 9,754,997,731.76 |
| Non-current liabilities: | ||
| Long-term loans | 3,666,476,993.70 | 3,230,844,042.88 |
| Bonds payable | ||
| Lease liabilities | 20,171,911.31 | 23,482,486.07 |
| Long-term payables | ||
| Long-term payroll payable | ||
| Estimated liabilities | ||
| Deferred income | 441,393,354.98 | 384,537,267.55 |
| Deferred income tax liabilities | 232,294,155.75 | 231,164,425.48 |
| Other non-current liabilities | 90,000,000.00 | 84,000,000.00 |
| Total non-current liabilities | 4,450,336,415.73 | 3,954,028,221.98 |
| Total liabilities | 13,845,357,862.33 | 13,709,025,953.74 |
| Owner's equity (or shareholder's equity): | ||
| Paid-in capital | 1,929,189,374.00 | 1,929,189,374.00 |
| Other equity instruments | ||
| In which: Preferred shares | ||
| Perpetual debts | ||
| Capital reserve | 2,541,441,353.22 | 2,343,693,215.99 |
| Less: Treasury shares | 717,135,581.08 | 347,176,561.29 |
| Other comprehensive income | -42,580,905.41 | 4,704,473.53 |
| Special reserve | ||
| Surplus reserve | 734,766,581.50 | 734,766,581.50 |
| Undistributed profits | 8,919,389,509.85 | 8,456,643,326.82 |
| Total owner's equity (or shareholder's equity) attributable to the parent company | 13,365,070,332.08 | 13,121,820,410.55 |
| Minority shareholder's equity | 8,982,622,820.65 | 8,898,407,287.12 |
| Total owner's equity (or shareholder's equity) | 22,347,693,152.74 | 22,020,227,697.67 |
| Total liabilities and owner's equity (or shareholder's equity) | 36,193,051,015.06 | 35,729,253,651.41 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Qiu Qingfeng
Consolidated Income StatementFrom January to March, 2023Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First quarter (January to March) for 2023 | First quarter (January to March) for 2022 |
| I. Total revenues | 4,559,049,786.82 | 4,657,343,538.89 |
| In which: Operating revenues | 4,559,049,786.82 | 4,657,343,538.89 |
| II. Total operating costs | 3,563,214,097.57 | 3,650,160,694.91 |
| In which: Operating costs | 1,713,465,807.02 | 1,611,006,712.60 |
| Operating tax and surcharges | 54,610,788.80 | 52,198,225.41 |
| Selling expenses | 1,220,569,090.59 | 1,413,289,256.99 |
| Administrative expenses | 209,257,340.10 | 252,854,561.35 |
| R&D expenses | 381,172,496.49 | 351,331,244.23 |
| Financial expenses | -15,861,425.43 | -30,519,305.67 |
| In which: Interest expenses | 33,036,361.57 | 29,854,923.66 |
| Interest income | 68,217,553.45 | 68,468,649.16 |
| Add: Other income | 54,191,288.49 | 59,138,624.91 |
| Income from investments (loss is indicated by“-”) | 39,625,949.95 | 29,176,808.52 |
| In which: Income from investments in associates and joint ventures | 11,470,389.65 | 15,204,632.53 |
| Gains from derecognition of financial assets at amortized cost | ||
| Gains from net exposure hedges (loss is indicated by“-”) | ||
| Gains from changes in fair values (loss is indicated by“-”) | -27,478,190.74 | -54,151,999.18 |
| Losses of credit impairment (loss is indicated by“-”) | -15,459,174.59 | 217,773.10 |
| Assets impairment loss (loss is indicated by“-”) | 1,837,691.27 | -5,309,013.21 |
| Gains from disposal of assets (loss is indicated by“-”) | -370,357.71 | |
| III. Operating profit (loss is indicated by“-”) | 1,048,553,253.63 | 1,035,884,680.41 |
| Add: Non-operating income | 876,580.36 | 2,321,933.96 |
| Less: Non-operating expenses | 3,698,829.74 | 2,084,578.34 |
| IV. Total profit (loss is indicated by“-”) | 1,045,731,004.25 | 1,036,122,036.03 |
| Less: Income tax expenses | 167,212,968.94 | 173,764,775.30 |
| V. Net profit (loss is indicated by“-”) | 878,518,035.31 | 862,357,260.73 |
| (I) Classified by business continuity | ||
| 1. Net profit from ongoing operation (loss is indicated by“-”) | 878,518,035.31 | 862,357,260.73 |
| 2. Net profit from discontinuing operation (loss is indicated by“-”) | ||
| (II) Classified by ownership | ||
| 1.Net profit attributable to shareholders of the parent company (loss is indicated by“-”) | 462,746,183.03 | 460,537,813.53 |
| 2.Profit and loss of minority shareholders (loss is indicated by“-”) | 415,771,852.27 | 401,819,447.20 |
| VI. Other comprehensive income, net of tax | -83,671,573.75 | -106,847,774.60 | ||
| (I) Other comprehensive income attributable to owners of the parent company, net of tax | -47,285,378.94 | -92,885,997.05 | ||
| 1. Other comprehensive income that cannot be reclassified into profit or loss | -20,803,179.78 | -75,513,312.70 | ||
| (1) Changes from remeasurement of defined benefit plans | ||||
| (2) Other comprehensive income that cannot be reclassified into profit or loss under the equity method | ||||
| (3) Changes in fair value of investments in other equity instruments | -20,803,179.78 | -75,513,312.70 | ||
| (4) Changes in fair value of the enterprise's own credit risks | ||||
| 2. Other comprehensive income that will be reclassified into profit or loss | -26,482,199.17 | -17,372,684.35 | ||
| (1) Other comprehensive income that can be reclassified into profit or loss under the equity method | ||||
| (2) Changes in fair value of other debt investments | ||||
| (3) Amount of financial assets reclassified into other comprehensive income | ||||
| (4) Provision for credit impairment of other debt investments | ||||
| (5) Reserve for cash flow hedges | ||||
| (6) Exchange translation differences on financial statements denominated in foreign currencies | -26,482,199.17 | -17,372,684.35 | ||
| (7) Others | ||||
| (II) Other comprehensive income attributable to minority shareholders, net of tax | -36,386,194.81 | -13,961,777.55 | ||
| VII. Total comprehensive income | 794,846,461.55 | 755,509,486.13 | ||
| (I) Total comprehensive income attributable to owners of the parent company | 415,460,804.09 | 367,651,816.48 | ||
| (II) Total comprehensive income attributable to minority shareholders | 379,385,657.46 | 387,857,669.65 | ||
| VIII. Earnings per share: | ||||
| (I) Basic earnings per share (RMB/share) | 0.2404 | 0.2411 | ||
| (II) Diluted earnings per share (RMB/share) | 0.2398 | 0.2410 | ||
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Qiu Qingfeng
Consolidated Cash Flow Statement
From January to March, 2023Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First quarter (January to March) for 2023 | First quarter (January to March) for 2022 |
| I. Cash flow from operating activities: | ||
| Cash received from sales of goods and rendering of services | 4,361,096,155.32 | 4,614,758,574.74 |
| Tax refunds received | 40,439,680.21 | 32,240,811.32 |
| Other cash received related to operating activities | 202,829,024.01 | 172,771,264.97 |
| Subtotal of cash inflow from operating activities | 4,604,364,859.54 | 4,819,770,651.03 |
| Cash paid for goods and services | 1,563,463,357.75 | 1,165,780,579.10 |
| Cash paid to and on behalf of employees | 820,337,183.05 | 758,821,581.15 |
| Payments of all types of taxes | 541,191,286.96 | 420,627,138.84 |
| Other cash paid related to operating activities | 1,431,288,281.07 | 1,602,636,874.96 |
| Subtotal of cash outflow in operating activities | 4,356,280,108.83 | 3,947,866,174.05 |
| Net cash flow from operating activities | 248,084,750.71 | 871,904,476.98 |
| II. Cash flow from investing activities: | ||
| Cash received from disposal of investment | 70,031,257.75 | 216,970,980.42 |
| Cash received from investment income | 26,244,584.66 | 6,832,308.83 |
| Net cash received from disposal of fixed assets, intangible assets and other long-term assets | 88,664.00 | 346,152.00 |
| Net cash received from disposal of subsidiaries and other business units | ||
| Other cash received related to investing activities | 297,605,105.05 | 7,668,394.07 |
| Subtotal of cash inflow from investing activities | 393,969,611.46 | 231,817,835.32 |
| Cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets | 244,675,030.69 | 277,850,093.60 |
| Cash paid for investment | 6,183,753.84 | 30,338,557.45 |
| Net cash paid for acquisition of subsidiaries and other business units | 12,461,951.59 | |
| Other cash paid related to investing activities | 202,160,184.88 | 1,537,021.94 |
| Subtotal of cash outflow in investing activities | 465,480,921.00 | 309,725,672.99 |
| Net cash flow from investing activities | -71,511,309.54 | -77,907,837.67 |
| III. Cash flow from financing activities: | ||
| Cash received from capital contribution | 53,414,701.36 | |
| In which: Cash received from investment by minority interests of subsidiaries | ||
| Cash received from borrowings | 1,249,525,870.74 | 1,923,486,837.26 |
| Other cash received related to financing activities | 130,847,366.53 | |
| Subtotal of cash inflow from financing activities | 1,249,525,870.74 | 2,107,748,905.15 |
| Cash repayments of amounts borrowed | 715,074,985.04 | 1,776,859,803.19 |
| Cash payments for interest expenses and distribution of dividends or profits | 41,156,153.68 | 19,177,786.10 |
| In which: Dividends and profit paid minority interests of subsidiaries | 359,270.18 | |
| Other cash payments related to financing activities | 611,939,083.83 | 248,996,762.52 |
| Subtotal of cash outflow in financing activities | 1,368,170,222.55 | 2,045,034,351.81 |
| Net cash flow from financing activities | -118,644,351.81 | 62,714,553.34 |
| IV. Effect of exchange rate fluctuations on cash and cash equivalents | -47,773,910.21 | -12,259,201.98 |
| V. Net increase in cash and cash equivalents | 10,155,179.14 | 844,451,990.66 |
| Add: Opening balance of cash and cash equivalents | 14,178,465,686.40 | 11,697,518,141.18 |
| VI. Closing balance of cash and cash equivalents | 14,188,620,865.54 | 12,541,970,131.84 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Qiu Qingfeng
Implementation of new accounting standards or interpretations of standards, for the first time from 2023involves adjustments to the financial statements at the beginning of the year
□Applicable √N/A
Hereby the announcement is made.
Joincare Pharmaceutical Group Industry Co., Ltd.
24 April, 2023